Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,132Revenue (TTM) $M88.1Net Margin (%)266Altman Z-Score5.6
Enterprise Value $M2,233EPS (TTM) $10.8Operating Margin %44.4Piotroski F-Score6
P/E(ttm)9.4Beneish M-Score0.3Pre-tax Margin (%)14.8Higher ROA y-yY
Price/Book5.410-y EBITDA Growth Rate %--Quick Ratio0.6Cash flow > EarningsN
Price/Sales25.05-y EBITDA Growth Rate %--Current Ratio0.6Lower Leverage y-yY
Price/Free Cash Flow123y-y EBITDA Growth Rate %91.7ROA % (ttm)45.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)80.7Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M20.9ROIC % (ttm)87.1Gross Margin Increase y-yY

Gurus Latest Trades with LGND

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDJoel Greenblatt 2016-06-30 Add0.07%$107.09 - $130.37
($118.77)
$ 102.25-14%Add 229.35%71,870
LGNDKen Fisher 2016-06-30 Add$107.09 - $130.37
($118.77)
$ 102.25-14%Add 2.56%72,390
LGNDJoel Greenblatt 2016-03-31 Buy 0.03%$85.79 - $108.42
($97.41)
$ 102.255%New holding21,822
LGNDKen Fisher 2015-12-31 Reduce$85.69 - $111.85
($99.19)
$ 102.253%Reduce -0.14%70,583
LGNDKen Fisher 2015-09-30 Reduce$82.1 - $111.25
($97.26)
$ 102.255%Reduce -12.31%70,683
LGNDKen Fisher 2015-06-30 Reduce$75.67 - $100.9
($87.3)
$ 102.2517%Reduce -1.59%80,608
LGNDJoel Greenblatt 2015-03-31 Sold Out -0.0016%$51.54 - $77.11
($61.42)
$ 102.2566%Sold Out0
LGNDJoel Greenblatt 2014-12-31 Reduce-0.26%$42.36 - $57.96
($52.25)
$ 102.2596%Reduce -99.32%3,766
LGNDKen Fisher 2014-12-31 Add0.01%$42.36 - $57.96
($52.23)
$ 102.2596%Add 132.31%81,908
LGNDJoel Greenblatt 2014-09-30 Add0.23%$46.99 - $64.52
($53.04)
$ 102.2593%Add 894.83%552,053
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 102.2557%New holding55,492
LGNDKen Fisher 2014-06-30 Buy $59.74 - $70.19
($65.09)
$ 102.2557%New holding36,908
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 102.2554%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 102.2595%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 102.25126%New holding6,136
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 102.25676%Sold Out0
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 102.25869%New holding10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.14)
$ 102.25742%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.16)
$ 102.25533%New holding4,483
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HIGGINS JOHN LCEO 2016-09-22Sell3,000$117.34-13.06view
KOZARICH JOHN WDirector 2016-09-07Sell1,000$115-11.3view
KOZARICH JOHN WDirector 2016-09-01Sell1,666$105.4-3.22view
FOEHR MATTHEW WPresident and COO 2016-08-05Sell12,500$122.14-16.48view
Berkman Charles SVP, Gen. Counsel & Secretary 2016-08-05Sell22,067$123.16-17.17view
KOZARICH JOHN WDirector 2016-08-01Sell1,000$137.57-25.85view
KOZARICH JOHN WDirector 2016-07-01Sell1,000$121.4-15.97view
KOZARICH JOHN WDirector 2016-06-01Sell1,000$117.42-13.12view
Herman Melanie JDirector of Accounting 2016-05-18Sell334$120.5-15.34view
Aryeh JasonDirector 2016-05-06Sell25,000$119.2-14.42view

Quarterly/Annual Reports about LGND:

News about LGND:

Articles On GuruFocus.com
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
RS Investment Increases Holdings in Ulta Salon, Noble Energy and Fortune Brands Dec 23 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 

More From Other Websites
Amgen's Multiple Myeloma Drug Kyprolis Fails in Phase III Sep 28 2016
Amgen's Multiple Myeloma Drug Bumbles Key Test Vs. Blockbuster Velcade Sep 27 2016
Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : September 27, 2016 Sep 27 2016
Kite Pharma Reports Favorable Data from Lymphoma Study Sep 27 2016
Regeneron, Sanofi Skin Disease Drug Under Priority Review Sep 26 2016
Endo Appoints New CEO, Keeps Q3 & '16 View, Stock Jumps Sep 26 2016
Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US :... Sep 26 2016
Ligand Inks CNS License Agreement with Seelos Therapeutics Sep 23 2016
Teva Reports Positive Phase III Tardive Dyskinesia Data Sep 23 2016
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 22 2016
Ligand Licenses Four Programs to Seelos Therapeutics Sep 22 2016
Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology Sep 19 2016
ETF’s with exposure to Ligand Pharmaceuticals, Inc. : September 19, 2016 Sep 19 2016
Ligand Enters OmniAb® License Agreement with TeneoBio, Inc. Sep 16 2016
Ligand (LGND) Commences Phase II Type II Diabetes Study Sep 14 2016
5 Biotech Stocks That Are Broker Favorites Sep 13 2016
Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes Sep 13 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)